Lori Coburn
Last active: 3/3/2020

  1. Serum Polyunsaturated Fatty Acids Correlate with Serum Cytokines and Clinical Disease Activity in Crohn's Disease. Scoville EA, Allaman MM, Adams DW, Motley AK, Peyton SC, Ferguson SL, Horst SN, Williams CS, Beaulieu DB, Schwartz DA, Wilson KT, Coburn LA (2019) Sci Rep 9(1): 2882
    › Primary publication · 30814550 (PubMed) · PMC6393448 (PubMed Central)
  2. Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis. Coburn LA, Singh K, Asim M, Barry DP, Allaman MM, Al-Greene NT, Hardbower DM, Polosukhina D, Williams CS, Delgado AG, Piazuelo MB, Washington MK, Gobert AP, Wilson KT (2019) Oncogene 38(7): 1067-1079
    › Primary publication · 30202097 (PubMed) · PMC6377304 (PubMed Central)
  3. Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma. Short SP, Barrett CW, Stengel KR, Revetta FL, Choksi YA, Coburn LA, Lintel MK, McDonough EM, Washington MK, Wilson KT, Prokhortchouk E, Chen X, Hiebert SW, Reynolds AB, Williams CS (2019) Oncogene 38(25): 5091-5106
    › Primary publication · 30858547 (PubMed) · PMC6586520 (PubMed Central)
  4. Dietary Arginine Regulates Severity of Experimental Colitis and Affects the Colonic Microbiome. Singh K, Gobert AP, Coburn LA, Barry DP, Allaman M, Asim M, Luis PB, Schneider C, Milne GL, Boone HH, Shilts MH, Washington MK, Das SR, Piazuelo MB, Wilson KT (2019) Front Cell Infect Microbiol : 66
    › Primary publication · 30972302 (PubMed) · PMC6443829 (PubMed Central)
  5. Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Singh K, Coburn LA, Asim M, Barry DP, Allaman MM, Shi C, Washington MK, Luis PB, Schneider C, Delgado AG, Piazuelo MB, Cleveland JL, Gobert AP, Wilson KT (2018) Cancer Res 78(15): 4303-4315
    › Primary publication · 29853605 (PubMed) · PMC6072585 (PubMed Central)
  6. Distinct Immunomodulatory Effects of Spermine Oxidase in Colitis Induced by Epithelial Injury or Infection. Gobert AP, Al-Greene NT, Singh K, Coburn LA, Sierra JC, Verriere TG, Luis PB, Schneider C, Asim M, Allaman MM, Barry DP, Cleveland JL, Destefano Shields CE, Casero RA, Washington MK, Piazuelo MB, Wilson KT (2018) Front Immunol : 1242
    › Primary publication · 29922289 (PubMed) · PMC5996034 (PubMed Central)
  7. BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability. Choksi YA, Reddy VK, Singh K, Barrett CW, Short SP, Parang B, Keating CE, Thompson JJ, Verriere TG, Brown RE, Piazuelo MB, Bader DM, Washington MK, Mittal MK, Brand T, Gobert AP, Coburn LA, Wilson KT, Williams CS (2018) Mucosal Immunol 11(5): 1363-1374
    › Primary publication · 29907869 (PubMed) · PMC6162166 (PubMed Central)
  8. Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling. Scoville EA, Allaman MM, Brown CT, Motley AK, Horst SN, Williams CS, Koyama T, Zhao Z, Adams DW, Beaulieu DB, Schwartz DA, Wilson KT, Coburn LA (2018) Metabolomics 14(1): 17
    › Primary publication · 29681789 (PubMed) · PMC5907923 (PubMed Central)
  9. MTG16 is a tumor suppressor in colitis-associated carcinoma. McDonough EM, Barrett CW, Parang B, Mittal MK, Smith JJ, Bradley AM, Choksi YA, Coburn LA, Short SP, Thompson JJ, Zhang B, Poindexter SV, Fischer MA, Chen X, Li J, Revetta FL, Naik R, Washington MK, Rosen MJ, Hiebert SW, Wilson KT, Williams CS (2017) JCI Insight 2(16)
    › Primary publication · 28814670 (PubMed) · PMC5621889 (PubMed Central)
  10. EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis. Hardbower DM, Coburn LA, Asim M, Singh K, Sierra JC, Barry DP, Gobert AP, Piazuelo MB, Washington MK, Wilson KT (2017) Oncogene 36(27): 3807-3819
    › Primary publication · 28263971 (PubMed) · PMC5501754 (PubMed Central)